Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Co-Diagnostics, Inc.    CODX

CO-DIAGNOSTICS, INC.

(CODX)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
11/30/2020 12/01/2020 12/02/2020 12/03/2020 12/04/2020 Date
11.72(c) 11.06(c) 10.97(c) 10.84(c) 11.04 Last
1 475 386 2 012 486 1 112 958 1 233 642 1 101 871 Volume
-1.43% -5.63% -0.81% -1.19% +1.85% Change
More quotes
Financials (USD)
Sales 2020 71,3 M - -
Net income 2020 42,0 M - -
Net Debt 2020 - - -
P/E ratio 2020 7,08x
Yield 2020 -
Sales 2021 118 M - -
Net income 2021 57,5 M - -
Net Debt 2021 - - -
P/E ratio 2021 5,55x
Yield 2021 -
Capitalization 306 M 306 M -
Capi. / Sales 2020 4,30x
Capi. / Sales 2021 2,59x
Nbr of Employees 39
Free-Float 93,4%
More Financials
Company
Co-Diagnostics, Inc. is a molecular diagnostics company. The Company is engaged in developing, manufacturing and marketing diagnostics technology. Its reagents are used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules, such as deoxyribonucleic acid and ribonucleic acid. It also sells diagnostic equipment from other manufacturers as self-contained lab systems (MDx device). 
More about the company
Notations Surperformance© of Co-Diagnostics, Inc.
Trading Rating : Investor Rating :
More Ratings
All news about CO-DIAGNOSTICS, INC.
11/24MAXIM GROUP & H.C. WAINWRIGHT ANALYS : CODX) Buy Rating with PTs of $20 and $29
AQ
11/17DIAGNOSTICS : Notice from the SEC of registration effectiveness
PU
11/17DIAGNOSTICS : Additional proxy soliciting materials - definitive
PU
11/17DIAGNOSTICS : Official notification to shareholders of matters to be brought to ..
PU
11/16DIAGNOSTICS : Management's Discussion and Analysis of Financial Condition and Re..
AQ
11/16CO-DIAGNOSTICS, INC. : Results of Operations and Financial Condition, Financial ..
AQ
11/03DIAGNOSTICS : Management's Discussion and Analysis of Financial Condition and Re..
AQ
11/02CO-DIAGNOSTICS, INC. : Non-Reliance on Previous Financials, Audits or Interim Re..
AQ
09/11DIAGNOSTICS : Announces Details to Access Presentation at H.C. Wainwright Global..
PU
08/20DIAGNOSTICS : Receives Enhanced U.S. Patent Protection for CoPrimer™ Techn..
PU
08/14THE LAW OFFICES OF FRANK R. CRUZ : Reminds Investors of Looming Deadline in the ..
BU
08/13DIAGNOSTICS : Management's Discussion and Analysis of Financial Condition and Re..
AQ
08/12DEADLINE ALERT : Bragar Eagel & Squire, P.C. Reminds Investors That a Class Acti..
BU
08/10DIAGNOSTICS : announces launch of Logix Smart COVID-19 test in Australia
AQ
07/21DIAGNOSTICS : ROSEN, GLOBAL INVESTOR COUNSEL, Reminds Co-Diagnostics, Inc. Inves..
BU
More news
News in other languages on CO-DIAGNOSTICS, INC.
05/26WALL STREET STOCK EXCHANGE : Les valeurs à suivre à Wall Street
More news
Chart CO-DIAGNOSTICS, INC.
Duration : Period :
Co-Diagnostics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CO-DIAGNOSTICS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Average target price 30,67 $
Last Close Price 10,84 $
Spread / Highest target 297%
Spread / Average Target 183%
Spread / Lowest Target 84,5%
EPS Revisions
Managers
NameTitle
Dwight Howard Egan Chairman, President & Chief Executive Officer
Reed L. Benson Chief Financial Officer & Secretary
Brent C. Satterfield Chief Technology Officer & Chief Science Officer
Richard S. Serbin Independent Director
Eugene Durenard Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
CO-DIAGNOSTICS, INC.1,110.90%306
SARTORIUS AG93.71%29 116
REVENIO GROUP OYJ57.14%1 330
CELLAVISION AB (PUBL)-4.35%864
ALPHATEC HOLDINGS, INC.54.12%858
VAREX IMAGING CORPORATION-46.56%624